Immutep Ltd
ASX:IMM
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.27
0.4806
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Immutep Ltd
Immutep Ltd
Capital Expenditures
Immutep Ltd
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Immutep Ltd
ASX:IMM
|
Capital Expenditures
-AU$82.7k
|
CAGR 3-Years
-74%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
2%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Capital Expenditures
-$271k
|
CAGR 3-Years
45%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
CSL Ltd
ASX:CSL
|
Capital Expenditures
-$1.3B
|
CAGR 3-Years
9%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-12%
|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Capital Expenditures
-AU$5.6m
|
CAGR 3-Years
-87%
|
CAGR 5-Years
-85%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Capital Expenditures
-AU$10.8m
|
CAGR 3-Years
-222%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Capital Expenditures
-AU$307k
|
CAGR 3-Years
20%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-4%
|
|
Immutep Ltd
Glance View
Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. The company is headquartered in Sydney, New South Wales. The firm is engaged in the development of LAG-3 immunotherapeutic products for cancer and autoimmune disease. The firm has four product candidates based on the LAG-3 immune control mechanism. Its lead product candidate, eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein, which is in later-stage clinical development for the treatment of cancer. Its second product candidate (IMP761) is in pre-clinical development for the treatment of autoimmune disease. The Company’s two licensed product candidates include Antagonist AB (LAG525) and Depleting AB (GSK‘781). The Company’s operates through its subsidiaries, which includes Immutep USA Inc, PRR Middle East FZ LLC, Immutep GmbH, Immutep Australia Pty Ltd, Immutep IP Pty Ltd and Immutep S.A.S.
See Also
What is Immutep Ltd's Capital Expenditures?
Capital Expenditures
-82.7k
AUD
Based on the financial report for Jun 30, 2024, Immutep Ltd's Capital Expenditures amounts to -82.7k AUD.
What is Immutep Ltd's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
2%
Over the last year, the Capital Expenditures growth was 0%. The average annual Capital Expenditures growth rates for Immutep Ltd have been -74% over the past three years , -15% over the past five years , and 2% over the past ten years .
You don't have any saved screeners yet
